Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 10/20 | 0.42 |
| ▸ | NR1H3 | Q13133 | 8/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | ADAMTS5 | Q9UNA0 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3604244 | 1.00 | NR1H2 (0.42) | NR1H2NR1H3LMNARECQLPOLB | |
| SCHEMBL102924 | 1.00 | NR1H2 (0.42) | NR1H2NR1H3LMNARECQLPOLB | |
| SCHEMBL3596593 | 0.92 | NR1H2 (0.44) | NR1H2NR1H3LMNARECQLPOLB | |
| SCHEMBL3596590 | 0.92 | NR1H2 (0.44) | NR1H2NR1H3LMNARECQLPOLB | |
| SCHEMBL13072521 | 0.91 | NR1H2 (0.44) | NR1H2NR1H3 | |
| SCHEMBL104254 | 0.85 | HTT (0.39) | NR1H2NR1H3POLBADAMTS5 | |
| SCHEMBL3590106 | 0.85 | HTT (0.39) | NR1H2NR1H3POLBADAMTS5 | |
| SCHEMBL3590100 | 0.85 | HTT (0.39) | NR1H2NR1H3POLBADAMTS5 | |
| SCHEMBL104619 | 0.85 | NR1H2 (0.31) | NR1H2NR1H3ADAMTS5 | |
| SCHEMBL144724 | 0.82 | NR1H2 (0.51) | NR1H2NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8551985-B2 | Carbinol derivatives having heterocyclic linker | KOWA COMPANY, LTD. (JP) | 2013-10-08 | — | — | US | disclosed |
| US-20100280013-A1 | CARBINOL DERIVATIVES HAVING HETEROCYCLIC LINKER | KOWA COMPANY, LTD. (JP) | 2010-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100280013-A1 | CARBINOL DERIVATIVES HAVING HETEROCYCLIC LINKER | NR1H2, NR1H3, CCR2 | NR1H2 1/4885NR1H3 2/4885LMNA 1575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.